![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/25/2904155/0/en/Annexon-Presented-Additional-Positive-Phase-3-Results-for-ANX005-C1q-Targeted-Immunotherapy-in-Guillain-Barr%C3%A9-Syndrome-at-the-2024-PNS-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/06/18/2900370/0/en/Annexon-To-Present-Pivotal-Phase-3-Data-On-Early-And-Durable-Benefits-With-First-In-Class-C1q-Blocking-Antibody-ANX005-In-Guillain-Barr%C3%A9-Syndrome-At-2024-PNS-Annual-Meeting.html
https://www.reuters.com/business/healthcare-pharmaceuticals/annexons-neurological-disorder-drug-meets-main-goal-late-stage-study-2024-06-04/
https://www.globenewswire.com/news-release/2024/06/06/2894382/0/en/Annexon-Announces-Pricing-of-125-Million-Underwritten-Public-Offering.html
https://www.globenewswire.com/news-release/2024/06/04/2892927/0/en/Annexon-Announces-Positive-Topline-Results-from-Pivotal-Phase-3-Trial-for-First-in-Class-C1q-Blocking-Antibody-ANX005-in-Guillain-Barr%C3%A9-Syndrome.html
https://www.globenewswire.com/news-release/2024/06/04/2893486/0/en/Annexon-Announces-Proposed-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com/news-release/2024/06/03/2892620/0/en/Annexon-Biosciences-to-Host-Conference-Call-and-Webcast-to-Discuss-GBS-Phase-3-Data.html
https://www.globenewswire.com/news-release/2024/05/16/2883865/0/en/Annexon-Reports-Inducement-Grants-to-New-Employees-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/13/2880367/0/en/Annexon-Reports-First-Quarter-2024-Financial-Results-and-Key-Anticipated-Milestones.html
https://www.globenewswire.com/news-release/2024/05/09/2878698/0/en/Annexon-Biosciences-to-Present-at-the-Bank-of-America-Health-Care-Conference.html